Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer

被引：0
|
作者：
Min Huang
M. Catherine Pietanza
Ayman Samkari
James Pellissier
Thomas Burke
Sheenu Chandwani
Fansen Kong
A. Simon Pickard
机构：
[1] Merck & Co.,Centre for Observational and Real
[2] Inc.,world Evidence
[3] Second City Outcomes Research,undefined
来源：
PharmacoEconomics | 2019年 / 37卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：105 / 116
页数：11
相关论文
共 50 条
  • [21] The Value of PD-L1 Expression in metastatic Lymph Nodes of Advanced Non-Small Cell Lung Cancer Response
    Perrotta, Fabio
    Kerr, Keith M.
    Navani, Neal
    CHEST, 2020, 158 (04) : 1787 - 1788
  • [22] Non-Small Cell Lung Cancer, PD-L1, and the Pathologist
    Kerr, Keith M.
    Nicolson, Marianne C.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2016, 140 (03) : 249 - 254
  • [23] Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients
    Nhung Pham
    Quyet Do
    Thang Ta
    Dung Nguyen
    Dai Do
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [24] An Exploratory Analysis of PD-L1 Expression and Smoking History in a Cohort of Advanced Non-Small Cell Lung Cancer Patients
    Decatris, M.
    Taniere, P.
    Hayes, M.
    Thomas, J.
    Gaikwad, K.
    Kalkat, M.
    Birchall, K.
    Osbaldiston, J.
    Phillips, A.
    Ryan, P.
    Reed, N.
    Du Rand, I.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S875 - S876
  • [25] Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice?
    Theelen, Willemijn S. M. E.
    Baas, Paul
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [26] Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
    Sugisaka, J.
    Sugawara, S.
    Toi, Y.
    Ogasawara, T.
    Aso, M.
    Tsurumi, K.
    Ono, K.
    Shimizu, H.
    Domeki, Y.
    Aiba, T.
    Kawana, S.
    Saito, R.
    Terayama, K.
    Kawashima, Y.
    Nakamura, A.
    Yamanda, S.
    Kimura, Y.
    Honda, Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] PD-L1 Expression and Response to Pembrolizumab in Japanese Patients with EGFR-Mutant Non-small Cell Lung Cancer
    Miyawaki, Eriko
    Murakami, Haruyasu
    Miyawaki, Taichi
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Nakashima, Kazuhisa
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Endo, Masahiro
    Takahashi, Toshiaki
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%
    Metro, Giulio
    Banna, Giuseppe Luigi
    Signorelli, Diego
    Gili, Alessio
    Galetta, Domenico
    Galli, Giulia
    Economopoulou, Panagiota
    Roila, Fausto
    Friedlaender, Alex
    Camerini, Andrea
    Christopoulou, Athina
    Cantale, Ornella
    De Toma, Alessandro
    Pizzutilo, Pamela
    Jimenez, Beatriz
    Collazo-Lorduy, Ana
    Calles, Antonio
    Baxevanos, Panagiotis
    Linardou, Helena
    Kosmidis, Paris
    Giannarelli, Diana
    Mountzios, Giannis
    Addeo, Alfredo
    JOURNAL OF IMMUNOTHERAPY, 2020, 43 (09) : 299 - 306
  • [29] Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
    Liao, Weiting
    Huang, Jiaxing
    Hutton, David
    Li, Qiu
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 344 - 349
  • [30] Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1
    Huang, Min
    O'Shaughnessy, Joyce
    Haiderali, Amin
    Pan, Wilbur
    Hu, Peter
    Chaudhuri, Mitashri
    De Tilleghem, Celine Le Bailly
    Cappoen, Nicolas
    Fasching, Peter A.
    EUROPEAN JOURNAL OF CANCER, 2022, 177 : 45 - 52
12345